09:51 AM EST, 11/07/2025 (MT Newswires) -- Summit Therapeutics ( SMMT ) said Friday that a phase 3 trial evaluating ivonescimab combined with platinum-doublet chemotherapy showed a "statistically significant benefit in overall survival" in patients with metastatic non-squamous non-small cell lung cancer.

The drug combination demonstrated a "clinically meaningful" improvement when compared with chemotherapy alone, the company said.

Shares of Summit Therapeutics ( SMMT ) were down 3.3% in recent trading.

Price: 17.95, Change: -0.50, Percent Change: -2.74